24608088 |
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia
Janke, H,
Pastore, F,
Schumacher, D,
Herold, T,
Hopfner, KP,
Schneider, S,
Berdel, WE,
Büchner, T,
Woermann, BJ,
Subklewe, M,
Bohlander, SK,
Hiddemann, W,
Spiekermann, K,
Polzer, H
|
|
2014 |
19808698 |
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
Yoshimoto, G,
Miyamoto, T,
Jabbarzadeh-Tabrizi, S,
Iino, T,
Rocnik, JL,
Kikushige, Y,
Mori, Y,
Shima, T,
Iwasaki, H,
Takenaka, K,
Nagafuji, K,
Mizuno, S,
Niiro, H,
Gilliland, GD,
Akashi, K
|
|
2009 |
29372308 |
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
Marhäll, A,
Heidel, F,
Fischer, T,
Rönnstrand, L
|
|
2018 |
15718420 |
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
Grundler, R,
Miething, C,
Thiede, C,
Peschel, C,
Duyster, J
|
|
2005 |
31066629 |
FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications
Kazi, JU,
Rönnstrand, L
|
Physiol. Rev. |
2019 |
17356133 |
Activation mechanisms of STAT5 by oncogenic Flt3-ITD
Choudhary, C,
Brandts, C,
Schwäble, J,
Tickenbrock, L,
Sargin, B,
Ueker, A,
Böhmer, FD,
Berdel, WE,
Müller-Tidow, C,
Serve, H
|
Blood |
2007 |
10698507 |
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
Hayakawa, F,
Towatari, M,
Kiyoi, H,
Tanimoto, M,
Kitamura, T,
Saito, H,
Naoe, T
|
Oncogene |
2000 |
28470536 |
FLT3-ITD and its current role in acute myeloid leukaemia
Lagunas-Rangel, FA,
Chávez-Valencia, V
|
|
2017 |
21359601 |
Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model
Chan, PM
|
|
2011 |
15769897 |
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
Choudhary, C,
Schwäble, J,
Brandts, C,
Tickenbrock, L,
Sargin, B,
Kindler, T,
Fischer, T,
Berdel, WE,
Müller-Tidow, C,
Serve, H
|
|
2005 |
15178581 |
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
Jiang, J,
Paez, JG,
Lee, JC,
Bo, R,
Stone, RM,
Deangelo, DJ,
Galinsky, I,
Wolpin, BM,
Jonasova, A,
Herman, P,
Fox, EA,
Boggon, TJ,
Eck, MJ,
Weisberg, E,
Griffin, JD,
Gilliland, DG,
Meyerson, M,
Sellers, WR
|
Blood |
2004 |
14984498 |
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia
Stirewalt, DL,
Meshinchi, S,
Kussick, SJ,
Sheets, KM,
Pogosova-Agadjanyan, E,
Willman, CL,
Radich, JP
|
Br. J. Haematol. |
2004 |
11290575 |
Point mutations in the FLT3 gene in AML
Griffin, JD
|
|
2001 |
8946930 |
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
Nakao, M,
Yokota, S,
Iwai, T,
Kaneko, H,
Horiike, S,
Kashima, K,
Sonoda, Y,
Fujimoto, T,
Misawa, S
|
|
1996 |
9737679 |
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
Kiyoi, H,
Towatari, M,
Yokota, S,
Hamaguchi, M,
Ohno, R,
Saito, H,
Naoe, T
|
Leukemia |
1998 |
29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Klug, LR,
Kent, JD,
Heinrich, MC
|
Pharmacol. Ther. |
2018 |
22411868 |
SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML
Leischner, H,
Albers, C,
Grundler, R,
Razumovskaya, E,
Spiekermann, K,
Bohlander, S,
Rönnstrand, L,
Götze, K,
Peschel, C,
Duyster, J
|
Blood |
2012 |
14759363 |
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
Griffith, J,
Black, J,
Faerman, C,
Swenson, L,
Wynn, M,
Lu, F,
Lippke, J,
Saxena, K
|
|
2004 |